Biotechnology major Biocon Q4 net profit surges 86% to Rs 296.4 crore
Biotechnology major Biocon has reported 86.29 per cent jump in consolidated profit to Rs 296.4 crore for the quarter ended March 31, 2021.
The company had reported profit of Rs 159.1 crore in the corresponding period a year ago.
Total income of the company rose by 26.13 per cent to Rs 2,044.1 crore as against Rs 1,620.6 crore for the same period year ago, the company said in a regulatory filing.
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, said: “In Q4FY21 our revenues grew 26 per cent year-on-year to Rs 2,044 crore driven by our biosimilars, research services and generics businesses”.
Mazumdar-Shaw said the Biocon Group is catering to the countrywide demand for Remdesivir, Itolizumab and CytoSorb.
“Syngene through its vaccination centre is offering immunisation services for Biocon Group employees as well to others operating in Electronic City, Bengaluru. Despite the challenges posed by the second COVID-19 wave in India, we will endeavour to have safe and uninterrupted operations and enable access to life-saving medicines for our patients and customers,” she added.
In a separate filing, the company said its board of directors has approved the stepping down of Anupam Jindal as Chief Financial Officer (CFO) with immediate effect.
The board also cleared the appointment of Indranil Sen as CFO with immediate effect.
Shares of Biocon were trading 1.47 per cent higher at Rs 396.70 apiece on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
